A Phase II Study of ARQ 501 [beta lapachone] in Combination With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma

Trial Profile

A Phase II Study of ARQ 501 [beta lapachone] in Combination With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Beta lapachone; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors ArQule
  • Most Recent Events

    • 08 Jan 2009 Status changed from active, no longer recruiting to completed, based on information from ClinicalTrials.gov.
    • 02 Nov 2007 Interim results have been reported: final results expected before the end of 2007.
    • 22 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top